References
- Bassetti M, Luyt CE, Nicolau DP, et al. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016;6(1):35.
- Metzler KL, Drlica K, Blondeau JM. Minimal inhibitory and mutant prevention concentrations for azithromycin, clarithromycin and erythromycin with clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2013;68(3):631–635.
- Blondeau JM, Hansen GT, Metzler KL, et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother. 2004;16(Suppl.3):1–19.
- Rodvold KA, Gotfried M, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 1997;41:1399–1402.
- Chaplin S. Topical antibacterial and antiviral agents: prescribing and resistance. Prescriber. 2016;27(7):29–36.
- Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009;49(10):1541–1549.
- Kaye S. Microbial keratitis and the selection of topical antimicrobials. BMJ Open Ophthalmol. 2017;1:1–3.
- Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. 2004;70(11):2125–2132.
- Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–189.
- American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
- Sandiumenge A, Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med. 2012;18(3):187–193.
- Slavcovici A, Maier C, Radulescu A. Antimicrobial resistance of ESKAPE-pathogens in culture positive pneumonia. Farmacia. 2015;63(2):201–205.
- Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent.). 2006;19(2):155–161.
- Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14.
- Dixit D, Madduri RP, Sharma R. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther. 2014;12(4):397–400.
- Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963–1971.
- Teo JW, Chew KL, Lin RT. Transmissible colistin resistance encoded by mcr-1 detected in clinical Enterobacteriaceae isolates in Singapore. Emerg Microbes Infect. 2016;5(8):e87.
- Mcphee JB, Lewenza S. From pigs to patients: transmissible, single gene-mediated resistance to colistin. J Med Microbiol Diagn. 2016;5(221).
- Webb HE, Granier SA, Marault M, et al. Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis. 2016;16(2):144–145.
- Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003–1012.
- Wunderink RG. POINT: should inhaled antibiotic therapy be used routinely for the treatment of bacterial lower respiratory tract infections in the ICU setting? Yes. Chest. 2017; 151(4): 737–739.
- Kollef MH. COUNTERPOINT: should inhaled antibiotic therapy be used routinely for the treatment of bacterial lower respiratory tract infections in the ICU setting? No. Chest. 2017;151(4):740–743.
- Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208.
- Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol. 2009;20:383–396.
- Blondeau JM, Shebelski SD. Killing of Enterobacter cloacae (Ecl), E. coli (Ec) and Klebsiella pneumoniae (Kp) by pulmonary drug concentration of ciprofloxacin dry powder for inhalation (Cdpi). In: 26th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands; 2016. Abstract #EV0394.
- Blondeau JM, Shebelski SD. Drug concentrations (DC) of ciprofloxacin below the mutant selection window (MSW) were not associated with resistance selection with Escherchia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae) and Pseudomonas aeruginosa (P. aeruginosa). In: International Congress of Chemotherapy and Infection. Taipei, Taiwan; 2017. Abstract #PS 312.